acquisition
ImClone Throws Down and Announces Additional Suitor
It was only a matter of time before the BMS/ImClone chatter picked up again. Today, ImClone has released a statement, again officially crapping on BMS’s unsolicited, $60/share offer and also chumming the waters with news of a different possible suitor.
“Mr. Icahn also announced he has had several conversations with the Chief Executive Officer of [...]
Shionogi Acquires Sciele Pharma for $1.4 Billion
The Japanese pharma spending spree continues…
Shionogi will acquire all the outstanding shares of Sciele’s common stock at a price of $31 (67% over yesterday’s close), for a total equity purchase price of approximately $1.1 billion. Upon completion of the acquisition, Sciele will become a wholly-owned subsidiary of Shionogi and will continue operations in Atlanta, GA, [...]
King Tenders All Cash $1.4B Unsolicited Bid For Alphama
Image via Wikipedia
Wasn’t it just a few weeks ago King Pharmaceuticals was trading 15% higher due to speculation Pfizer was buying them?
How many different ways are there to spell “market manipulation”? Methinks not more than one.
King announced today that it has submitted a [...]
Genentech Drops The Other Shoe
We all knew it was just a matter of time until the “special committee” appointed to review the Roche officially rejected the buyout offer of $89/share.
The press release indicates a willingness to listen to offers that “recognizes the value of the company and reflects the significant benefits that would accrue” to an acquiring company.
Move along [...]
Roche on Spending Spree
First Roche offers to buy Genentech for ~$44B and in two consecutive days has inked two more deals.
Yesterday, in its second RNAi play in a year, Roche bought Mirus Bio for $125M. The acquisition should add value to the July 2007 preclinical discovery deal with RNAi leader Alnylam. Under the agreement, Mirus will [...]
Shire Ponies Up For Jerini
Image via Wikipedia
Shire and its well known acquisition strategy are at it again, this time buying Berlin-based, Jerini for $521.2M (a 71% premium).
The rationale for the deal was the addition of Firazyr, an orphan drug treatment for hereditary angioedema (HAE), which received a not approvable letter from the FDA in April but has an EU [...]
Rumor Mill: Pfizer Buying MediGene?
The German based, MediGene hit a 52 week high yesterday on rumors that they are in discussions with the drug giant Pfizer. MediGene is just the latest of half a dozen companies mentioned in the same sentence as Pfizer in the last few months (others include Biogen, Shire, King and NicOx).
In the past year, [...]
Recent Comments